Values as of: 2024-10-30
COMMON STOCK | Healthcare Plans |
Last Closing
USD 410.76Change
+0.19 (+0.05)%Market Cap
USD 96.37BVolume
1.93MAnalyst Target
N/AVerdict
Verdict
Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. The company operates in the pharmacy services business; and markets and offers pharmacy services, including pharmacy benefit management, as well as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services. In addition, it provides healthcare-related services and capabilities, including utilization management, behavioral health, integrated care delivery, palliative care, payment integrity services, subrogation services, and health and wellness programs, as well as services related to data management, information technology, and business operations. Further, the company is involved in the National Government Services business. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brand names. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.
Company Website : https://www.elevancehealth.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| UNH | UnitedHealth Group Incorporate.. |
+0.83 (+0.15%) |
USD 521.40B |
| CNC | Centene Corp |
+1.16 (+1.91%) |
USD 32.42B |
| MOH | Molina Healthcare Inc |
+1.06 (+0.33%) |
USD 18.62B |
| OSCR | Oscar Health Inc |
+1.11 (+6.97%) |
USD 3.86B |
| NEUE | NeueHealth Inc |
+0.06 (+1.20%) |
USD 0.05B |
| CI | Cigna Corp |
+4.66 (+1.51%) |
N/A |
| CVS | CVS Health Corp |
+0.14 (+0.25%) |
N/A |
| HUM | Humana Inc |
+8.55 (+3.32%) |
N/A |
| Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|---|
| ZWHC:CA | BMO Covered Call Health C.. | 4.88 % | 0.00 % |
-0.20 (-0.66%) |
N/A |
| WHCS:SW | iShares MSCI World Health.. | 3.67 % | 0.00 % |
N/A |
N/A |
| CBUF:F | iShares V Public Limited .. | 3.37 % | 0.00 % |
-0.08 (-0.66%) |
N/A |
| AILV | 3.21 % | 0.00 % |
N/A |
N/A | |
| CBUF:XETRA | iShares MSCI World Health.. | 2.88 % | 0.00 % |
-0.09 (-0.66%) |
USD 1.13B |
| WELG:XETRA | Amundi S&P Global Health .. | 2.53 % | 0.00 % |
-0.14 (-0.66%) |
N/A |
| WELS:XETRA | Amundi S&P Global Health .. | 2.53 % | 0.00 % |
-0.14 (-0.66%) |
N/A |
| ESGI:AU | VanEck MSCI International.. | 2.46 % | 0.00 % |
-0.04 (-0.66%) |
USD 0.19B |
| TEQI | T. Rowe Price Equity Inco.. | 2.30 % | 0.00 % |
+0.01 (+-0.66%) |
USD 0.25B |
| H41D:XETRA | HSBC MSCI World Value ESG.. | 2.16 % | 0.00 % |
-0.15 (-0.66%) |
N/A |
| PYF-B:CA | Purpose Fund Corp. - Purp.. | 0.64 % | 0.00 % |
N/A |
N/A |
| PYF-U:CA | Purpose Fund Corp. - Purp.. | 0.64 % | 0.00 % |
N/A |
N/A |
| IHF | iShares U.S. Healthcare P.. | 0.00 % | 0.43 % |
-0.13 (-0.66%) |
N/A |
| RYH | 0.00 % | 0.40 % |
N/A |
N/A | |
| PBI-B:CA | Purpose Fund Corp. - Purp.. | 0.00 % | 0.00 % |
+0.46 (+-0.66%) |
N/A |
| Market Performance vs. Industry/Classification (Healthcare Plans) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | -12.89% | 88% | B+ | 20% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -12.89% | 88% | B+ | 29% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | -8.04% | 88% | B+ | 18% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -8.04% | 88% | B+ | 26% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 2.55% | 38% | F | 45% | F | ||
| Dividend Return | 3.11% | 25% | F | 38% | F | ||
| Total Return | 0.56% | 20% | F | 14% | F | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 9.32% | 100% | F | 80% | B- | ||
| Risk Adjusted Return | 33.41% | 50% | F | 50% | F | ||
| Market Capitalization | 96.37B | 83% | B | 98% | N/A | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The company has under performed its peers on annual average total returns in the past 5 years.
